Financial reports
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
17 Nov 22
Current reports
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
22 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Dec 23
8-K
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
12 Oct 23
8-K
Settlement and Exchange Agreement
2 Oct 23
8-K
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
9 Aug 23
8-K
Template of Form of Phantom Stock Award Agreement
13 Jun 23
8-K
Entry into a Material Definitive Agreement
24 May 23
8-K
Regulation FD Disclosure
5 May 23
Registration and prospectus
253G2
Offering circular supplement
8 Mar 22
253G2
Offering circular supplement
17 Feb 22
253G2
Offering circular supplement
10 Jan 22
253G2
Offering circular supplement
3 Jan 22
253G2
Offering circular supplement
14 Dec 21
253G2
Offering circular supplement
14 Dec 21
253G3
Offering circular supplement
14 Dec 21
1-A/A
Offering $7.5M in Equity
1 Dec 21
1-A/A
Offering $7.5M in Equity
12 Oct 21
1-A
Offering $7.5M in Equity
9 Aug 21
Proxies
DEF 14A
Definitive proxy
30 Oct 20
PRER14A
Preliminary revised proxy
30 Oct 20
PRE 14A
Preliminary proxy
20 Oct 20
DEF 14C
Information statement
10 Apr 20
PRE 14C
Preliminary information
24 Mar 20
DEF 14A
Definitive proxy
8 Jul 16
PRE 14A
Preliminary proxy
7 Jun 16
DEF 14C
Information statement
13 May 15
PRER14C
Preliminary revised information
11 May 15
PRE 14C
Preliminary information
23 Apr 15
Other
QUALIF
Notice of qualification
14 Dec 21
CORRESP
Correspondence with SEC
9 Dec 21
UPLOAD
Letter from SEC
12 Aug 21
UPLOAD
Letter from SEC
2 Nov 20
EFFECT
Notice of effectiveness
29 Oct 20
UPLOAD
Letter from SEC
28 Oct 20
CORRESP
Correspondence with SEC
28 Oct 20
CORRESP
Correspondence with SEC
26 Oct 20
UPLOAD
Letter from SEC
16 Oct 20
CT ORDER
Confidential treatment order
20 Dec 18